We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An American biomaterials and biosurgical device company recently partnered with a laboratory in the UK to further explore the possibility of using animal tissue for human transplantation.
Building relationships with patient advocacy groups can help pharmaceutical firms speed the drug-development process, including during the all-important clinical trial phases, experts told the Biotechnology Industry Organization (BIO) annual conference.
Roughly half of the products large drugmakers receive approval for today are generated from in-licensed molecules, according to an industry expert, who said drugmakers can find particularly high value in acquisitions of large-molecule biologic products.
New Jersey-based drugmaker Wyeth has launched a broad restructuring program that will result in significant reductions to its main sales force, a company spokesman said Monday.
Mylan Laboratories is seeking a licensee for its highly anticipated beta-blocker nebivolol and could select a partner as early as this fall, company officials said during a June 14 conference call.
Novartis has completed its acquisition of German drugmaker Hexal, moving the company one step closer to becoming the industry’s largest generic pharmaceutical firm.
Financier Carl Icahn has again expressed interest in buying generic drugmaker Mylan Laboratories, indicating in a letter sent last week that he is willing to pay $20 per share for the firm.
Novartis has agreed to sell products in three European countries to gain final European Union (EU) approval for its planned merger of German generic drugmaker Hexal AG and Hexal’s U.S. sister company Eon Labs, the European Commission (EC) announced May 27.